Last reviewed · How we verify
Low dose Rosuvastatin
At a glance
| Generic name | Low dose Rosuvastatin |
|---|---|
| Also known as | Rosuvastatin Calcium, Crestor |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) (NA)
- Comparison of High and Moderate Intensity Statins in Achieving the Target LDL-C Level After Acute Coronary Syndrome (NA)
- Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
- Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI (PHASE4)
- Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention (PHASE4)
- Polypill in Acute Coronary Syndrome (PHASE2)
- A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. (PHASE1)
- VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose Rosuvastatin CI brief — competitive landscape report
- Low dose Rosuvastatin updates RSS · CI watch RSS
- Nanjing First Hospital, Nanjing Medical University portfolio CI